Tag:

Biotech deals

Latest Headlines

Latest Headlines

Map inks $157M co-promotion pact with Allergan

Allergan has agreed to pay Map Pharmaceuticals $60 million upfront and promised up to $97 million more for the right to co-promote the new migraine drug Levadex, which is poised for a regulatory

REPORT: Genzyme, Sanofi near merger deal

Reuters is reporting this morning that Genzyme and Sanofi-Aventis have reached an agreement in principal on a merger deal. Quoting sources familiar with the talks, the news wire says that the pact

Alexion snaps up Taligen for $111M-plus, creates translational unit

The promising protein drug developer Taligen Therapeutics is being snapped up by Alexion Pharmaceuticals for $111 million upfront and an undisclosed package of milestones for six of its drug

Ligand snaps up CyDex in $35.5M buyout

With one eye on adding revenue to the books and another focused on new delivery technology, San Diego-based Ligand Pharmaceuticals ($LGND) has snagged CyDex Pharmaceuticals for $31.2 million in cash

Amgen bets $1B on BioVex's dual-mechanism cancer therapy

In a bold late-stage gamble, Amgen has agreed to pay $425 million in cash to license a promising cancer vaccine from Woburn, MA-based BioVex, a 2009 Fierce 15 company which migrated to the U.S.

Pfizer, Theraclone ink $632 R&D deal for cancer, infectious disease

Seattle-based biotech Theraclone as signed a deal with Pfizer in which the company will use its I-STAR platform technology to help the Big Pharma identify monoclonal antibodies against up to four

Pfizer ups ante on Santaris RNA discovery deal with $614M pact

Two years after Pfizer ($PFE) inherited Wyeth's discovery pact with Denmark's Santaris, its researchers have decided to significantly up the ante on their deal. The pharma giant is handing over $14

Xoma snags $505 million pact on its top drug prospect

Xoma announced its long-anticipated licensing pact on the promising anti-inflammatory drug 052 this morning, snagging a $505 million pact and fueling a further surge in its sizzling share price. But

2010: Partnering takes on fresh urgency

Chris Viehbacher (photo) wasn't playing around when he said that Sanofi-Aventis ($SNY) was going to turn to outside partners for more of its innovative thinking. He spent much of 2010 breaking the

Biogen scoops up CNS programs in $427M acquisition deal

After three years of partnering with Switzerland's Neurimmune Therapeutics on antibody discovery programs targeting the CNS field, Biogen Idec ($BIIB) has opted to seal their deal with a pact to